CODX vs CRL · rev $3.9M vs rev $4.05B
Co-Diagnostics, Inc. Common Stock (CODX) versus Charles River Laboratories (CRL) — a side-by-side from cached financials, not a winner call.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
Latest reported CRL revenue for 2024-12-28 was $4.05B. Net income was $25.3M. Revenue was down 1.9% from 2023-12-30 to 2024-12-28. CRL currently screens at market cap $7.78B.
CODX currently screens at market cap $31.4M. CRL currently screens at market cap $7.78B.
Not investment advice. Open the CODX and CRL stock pages for the full models.
Not investment advice.